BRPI0412190A - sólidos com camada de difusão modulada - Google Patents

sólidos com camada de difusão modulada

Info

Publication number
BRPI0412190A
BRPI0412190A BRPI0412190-2A BRPI0412190A BRPI0412190A BR PI0412190 A BRPI0412190 A BR PI0412190A BR PI0412190 A BRPI0412190 A BR PI0412190A BR PI0412190 A BRPI0412190 A BR PI0412190A
Authority
BR
Brazil
Prior art keywords
diffusion layer
modulated
solids
drug
poorly soluble
Prior art date
Application number
BRPI0412190-2A
Other languages
English (en)
Inventor
Michael Hawley
Walter Morozowich
Michael S Bergren
John W Skoug
Philip R Nixon
John M Heimlich
Ping Gao
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BRPI0412190A publication Critical patent/BRPI0412190A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"SóLIDOS COM CAMADA DE DIFUSãO MODULADA". A presente invenção refere-se aos sólidos modulados pela cadeia de difusão, que incluam um excipiente e um sal solúvel de um fármaco básico e pouco solúvel; um sal solúvel de um fármaco ácido pouco solúvel; ou um fármaco não-ionizável e pouco solúvel, são úteis, por exemplo, para a melhoria da veiculação de fármacos.
BRPI0412190-2A 2003-07-01 2004-06-29 sólidos com camada de difusão modulada BRPI0412190A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48420503P 2003-07-01 2003-07-01
PCT/US2004/021143 WO2005004763A1 (en) 2003-07-01 2004-06-29 Diffusion layer modulated solids

Publications (1)

Publication Number Publication Date
BRPI0412190A true BRPI0412190A (pt) 2006-08-22

Family

ID=34062033

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412190-2A BRPI0412190A (pt) 2003-07-01 2004-06-29 sólidos com camada de difusão modulada

Country Status (9)

Country Link
US (1) US20050042291A1 (pt)
EP (1) EP1643948A1 (pt)
JP (1) JP2007527394A (pt)
AR (1) AR044983A1 (pt)
BR (1) BRPI0412190A (pt)
CA (1) CA2531116A1 (pt)
MX (1) MXPA06000178A (pt)
TW (1) TW200514576A (pt)
WO (1) WO2005004763A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
CN102917695A (zh) * 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
DE102011113749A1 (de) * 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
CN103889414A (zh) * 2011-10-18 2014-06-25 拉夸里亚创药株式会社 药物组合物
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2021096925A1 (en) * 2019-11-12 2021-05-20 W. L. Gore & Associates, Inc. Drug coated balloon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4028772A (en) * 1971-04-02 1973-09-27 Merck & Co., Inc Chemical processes
US4355091A (en) * 1980-08-25 1982-10-19 Polaroid Corporation Polymeric neutralizing layer with temporary crosslinks from an organo-metallic crosslinking agent
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
ZA984514B (en) * 1997-05-29 1998-11-30 Merck & Co Inc Hiv protease inhibitor
AU753241C (en) * 1998-06-11 2003-05-08 Pharmacia & Upjohn Company Tablet formation
CN1156461C (zh) * 1999-03-24 2004-07-07 R·P·希拉技术股份有限公司 改良的水溶性药物制剂
BR0016555A (pt) * 1999-12-23 2002-09-17 Pfizer Prod Inc Composições farmacêuticas que proporcionam concentrações acrescidas de droga
ES2333645T3 (es) * 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.

Also Published As

Publication number Publication date
TW200514576A (en) 2005-05-01
MXPA06000178A (es) 2006-04-11
CA2531116A1 (en) 2005-01-20
US20050042291A1 (en) 2005-02-24
WO2005004763A1 (en) 2005-01-20
AR044983A1 (es) 2005-10-12
JP2007527394A (ja) 2007-09-27
EP1643948A1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
BR0208338A (pt) Derivados de piridina
BR0215731A (pt) Polìmero sensìvel ao ph
DE60007095T2 (de) Calanolide zur hemmung von btk
BRPI0508744A (pt) sistema de retenção gástrica e processo para revestir um comprimido ou cápsula
WO2007113648A3 (en) Ctla4 antibody combination therapy
CY1113679T1 (el) Απταμερες εναντι midkine και χρηση αυτου
ECSP024341A (es) Composiciones farmaceuticas
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
BRPI0600777A (pt) método e sistema para a criação, armazenamento, gerenciamento e consumo de dados especìficos de cultura
EP1706128A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR INSULIN TREATMENT
BRPI0516577A (pt) agentes terapêuticos com toxicidade diminuìda
BRPI0412190A (pt) sólidos com camada de difusão modulada
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
MA29481B1 (fr) Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase
BRPI0620229A8 (pt) formulação
WO2008078109A3 (en) Medicament
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
ATE478156T1 (de) Verfahren zur identifizierung von modulatoren der eoxin-bildung
DK1602669T3 (da) Antistof mod et tumor-specifikt antigen som target
BRPI0516922A (pt) composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
BRPI0417993A (pt) anticorpo anti-cd52 para tratamento da diabetes
MY140530A (en) Antineoplasic compounds and pharmaceuticals compositions thereof
BR0317425A (pt) Sal de rabeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
EA200800150A1 (ru) Состав с пролонгированным высвобождением действующих начал лекарственного средства

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.